Takako Eguchi Nakajima

14PUBLICATIONS
100CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Sep 08, 2026
Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102.

|Aug 27, 2026
Phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases (WJOG10517G), including an individual patient data comparison with JCOG1108/WJOG7312G.

|May 22, 2026
Web questionnaire survey of physicians and patients on the side effects of trifluridine/tipiracil.

|May 01, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

|Jan 09, 2024
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer.

Yu Sunakawa, Yasutoshi Kuboki, Jun Watanabe

|Nov 17, 2023
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).

Hiroko Minatogawa, Naoki Izawa, Kazuhiro Shimomura

Pageof 3

Frequent Collaborators

3 joint publications

Takuro Mizukami

3 joint publications

Yasutoshi Kuboki

2 joint publications

Yu Sunakawa

2 joint publications

Takashi Ogura